These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19812599)

  • 1. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.
    Sargent JL; Milano A; Bhattacharyya S; Varga J; Connolly MK; Chang HY; Whitfield ML
    J Invest Dermatol; 2010 Mar; 130(3):694-705. PubMed ID: 19812599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.
    Farina G; Lemaire R; Pancari P; Bayle J; Widom RL; Lafyatis R
    Ann Rheum Dis; 2009 Mar; 68(3):435-41. PubMed ID: 18408251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subsets in the gene expression signatures of scleroderma skin.
    Milano A; Pendergrass SA; Sargent JL; George LK; McCalmont TH; Connolly MK; Whitfield ML
    PLoS One; 2008 Jul; 3(7):e2696. PubMed ID: 18648520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
    Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis.
    Avouac J; Clemessy M; Distler JH; Gasc JM; Ruiz B; Vacher-Lavenu MC; Wipff J; Kahan A; Boileau C; Corvol P; Allanore Y
    Rheumatology (Oxford); 2011 Aug; 50(8):1494-504. PubMed ID: 21454305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies.
    Altorok N; Tsou PS; Coit P; Khanna D; Sawalha AH
    Ann Rheum Dis; 2015 Aug; 74(8):1612-20. PubMed ID: 24812288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis.
    Bhattacharyya S; Sargent JL; Du P; Lin S; Tourtellotte WG; Takehara K; Whitfield ML; Varga J
    PLoS One; 2011; 6(9):e23082. PubMed ID: 21931594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.
    Sonnylal S; Denton CP; Zheng B; Keene DR; He R; Adams HP; Vanpelt CS; Geng YJ; Deng JM; Behringer RR; de Crombrugghe B
    Arthritis Rheum; 2007 Jan; 56(1):334-44. PubMed ID: 17195237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis.
    Manneschi LI; Del Rosso A; Milia AF; Tani A; Nosi D; Pignone A; Generini S; Giacomelli R; Cerinic MM
    Rheumatology (Oxford); 2005 May; 44(5):607-13. PubMed ID: 15728417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis.
    Farina GA; York MR; Di Marzio M; Collins CA; Meller S; Homey B; Rifkin IR; Marshak-Rothstein A; Radstake TR; Lafyatis R
    J Invest Dermatol; 2010 Nov; 130(11):2583-93. PubMed ID: 20613770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
    Piera-Velazquez S; Jimenez SA
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis - a cross-sectional study.
    Juhl P; Vinderslev Iversen L; Karlsmark T; Asser Karsdal M; Bay-Jensen AC; Mogensen M; Siebuhr AS
    Biomarkers; 2019 Jun; 24(4):373-378. PubMed ID: 30821519
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta.
    Bhattacharyya S; Ghosh AK; Pannu J; Mori Y; Takagawa S; Chen G; Trojanowska M; Gilliam AC; Varga J
    Arthritis Rheum; 2005 Apr; 52(4):1248-58. PubMed ID: 15818659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cancer-associated glycan polysialic acid is dysregulated in systemic sclerosis and is associated with fibrosis.
    Khan L; Derksen T; Redmond D; Storek J; Durand C; Gniadecki R; Korman B; Cohen Tervaert JW; D'Aubeterre A; Osman MS; Willis LM
    J Autoimmun; 2023 Nov; 140():103110. PubMed ID: 37742510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.
    Pannu J; Gore-Hyer E; Yamanaka M; Smith EA; Rubinchik S; Dong JY; Jablonska S; Blaszczyk M; Trojanowska M
    Arthritis Rheum; 2004 May; 50(5):1566-77. PubMed ID: 15146427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach.
    Corriveau MP; Boufaied I; Lessard J; Chabaud S; Senécal JL; Grodzicky T; Chartier S; Raymond Y; Moulin VJ
    J Pathol; 2009 Mar; 217(4):534-42. PubMed ID: 19086038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
    Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin involvement in scleroderma--where histological and clinical scores meet.
    Verrecchia F; Laboureau J; Verola O; Roos N; Porcher R; Bruneval P; Ertault M; Tiev K; Michel L; Mauviel A; Farge D
    Rheumatology (Oxford); 2007 May; 46(5):833-41. PubMed ID: 17255134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.